Francesca Barone, CSO of Candel Therapeutics, was recently interviewed by Benzinga.<br /><br />Candel is a clinical-stage biopharmaceutical company focused on developing immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The company has two main platforms that are currently undergoing clinical trials. <br /><br />Ms. Barone spoke about the company's work in deadly brain cancers. Its candidate, CAN-3110, is currently undergoing phase 1 trials. It recently published exciting data from the trial showing promising results.
